Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AVP-786

- PMLiVE

Lundbeck and Otsuka’s Rexulti set for August launch in US

Follows the antipsychotic drug's FDA approval on Friday

- PMLiVE

Ten new medicines recommended in Europe

Includes double approvals for rare disease specialist Alexion and Novartis

Biogen Idec building

Biogen Idec plans phase III Alzheimer’s trial before year-end

And MS drugs drive 2014 sales          

EU flag

Pharma joins European Alzheimer’s research initiative

Lilly and Janssen among participants of dementia-focused IMI project

- PMLiVE

Double trial disappointment for Roche

Discontinues Alzheimer’s programme and finds Kadcyla no better than Herceptin in certain breast cancer

- PMLiVE

Alzheimer’s charity launches £20m trials fund

Aims to fast-track research into dementia treatments

- PMLiVE

Otsuka expands CNS presence with Avanir purchase

Deal for US biotech is valued at $3.5bn

Novartis building

Novartis launches Alzheimer’s prevention study

Will test two treatments in people with genetic risk of dementia

- PMLiVE

Another Alzheimer’s failure as Targacept trial disappoints

Targacept drops development of drug after disappointing study results

- PMLiVE

Otsuka and Lundbeck file Abilify follow-up in the US

Brexpiprazole to be reviewed for use in schizophrenia and major depressive disorder

- PMLiVE

Otsuka launches European ADPKD forum

Aims to lead awareness raising plans for rare genetic condition

- PMLiVE

AFFiRiS claims a first in Alzheimer’s disease therapy

Says AD04 is first drug to demonstrate disease modification

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links